Scientists explain the resistance of Koch’s bacillus to drugs and immunity

Voiced by Amazon Polly

A consortium of researchers from Russia, Belarus, Japan, Germany, and France, led by a Skoltech scientist, has unveiled a way for Mycobacterium tuberculosis to survive.

Many years after the discovery, an international team of scientists managed to figure out how the tuberculosis bacterium “dodges” the treatment and the immune response.

Mycobacterium tuberculosis survives iron deficiency by using rubredoxin B, a protein from the rubredoxin family. They play an important role in the adaptation of organisms to changing environmental conditions. The research results are published by the journal Bioorganic Chemistry.

According to the World Health Organization (WHO), every year, 10 million people contract tuberculosis, and about 1.5 million die from it. The bacterium that causes tuberculosis, Mycobacterium tuberculosis, is known for its ability to survive in macrophages. These are cells of the immune system that destroy harmful bacteria that enter the body. The spread of drug resistance of M. tuberculosis to widely used therapeutic agents has become a significant clinical problem in recent decades. In this regard, the identification of new molecular drug targets and the deciphering of the molecular mechanisms of drug resistance are critical.

Author: John Kessler
Graduated From the Massachusetts Institute of Technology. Previously, worked in various little-known media. Currently is an editor and developer of Free News.
Function: Director